Dimension Therapeutics
Acquired by Ultragenyx Pharmaceuticals
AAV gene therapy developer for rare diseases.
AAV gene therapy developer for rare diseases.


F-Prime Team
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
2013
Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ: RARE).
